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Summary Purpose To establish the recommended phase II
dose of the oral γ-secretase inhibitor RO4929097 (RO) in
combination with gemcitabine; secondary objectives include
the evaluation of safety, tolerability, pharmacokinetics, bio-
markers of Notch signaling and preliminary anti-tumor activ-
ity. Methods Patients with advanced solid tumors were
enrolled in cohorts of escalating RO dose levels (DLs).
Tested RO DLs were 20 mg, 30 mg, 45 mg and 90 mg. RO
was administered orally, once daily on days 1–3, 8–10, 15–17,
22–24. Gemcitabine was administered at 1,000 mg/m2 on d1,
8, and 15 in 28 d cycles. Dose limiting toxicities (DLTs) were
assessed by CTCAE v4. Serial plasma was collected for RO
(total and unbound) and gemcitabine pharmacokinetic
analysis. Biomarkers of Notch signaling were assessed by
immunohistochemistry in archival tissue. Antitumor activity
was evaluated (RECIST 1.1). Results A total of 18 patients
were enrolled to establish the recommended phase II dose. Of
these, 3 patients received 20 mg RO, 7 patients received
30 mg RO, 6 patients received 45 mg RO and 2 patients
received 90 mg RO. DLTs were grade 3 transaminitis
(30 mg RO), grade 3 transaminitis and maculopapular rash
(45 mg RO), and grade 3 transaminitis and failure to receive
75 % of planned RO doses secondary to prolonged neutrope-
nia (90 mg); all were reversible. The maximum tolerated dose
was exceeded at 90 mg RO. Pharmacokinetic analysis of both
total and free RO confirmed the presence of autoinduction at
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45 and 90 mg. Median levels of Notch3 staining were higher
in individuals who received fewer than 4 cycles (p=0.029).
Circulating angiogenic factor levels did not correlate with time
to progression or ≥ grade 3 adverse events. Best response
(RECIST 1.1) was partial response (nasopharyngeal cancer)
and stable disease >4 months was observed in 3 patients
(pancreas, tracheal, and breast primary cancers). Conclusions
RO and gemcitabine can be safely combined. The
recommended phase II dose of
RO was 30 mg in combination with gemcitabine
1,000 mg/m2. Although RO exposure was limited by the
presence of autoinduction, RO levels achieved exceeded the
area under the concentration-time curve for 0–24 h (AUC0–24)
predicted for efficacy in preclinical models using daily dosing.
Evidence of clinical antitumor activity and prolonged stable
disease were identified.
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Introduction
Aberrations in the Notch signaling axis have been implicated
in the uncontrolled growth of malignant cells [1, 2]. Notch is a
cell surface receptor comprised of four paralogues (Notch 1–
4) and five canonical ligands including the Delta-like ligands
(DLL-1, DLL-3, DLL-4 and Jagged 1 and 2). Ligand binding
results in gamma-secretase induced intramembrane cleavage
and subsequent formation of the Notch intracellular domain
(NICD). NICD translocates into the nucleus and activates tran-
scription of target genes includingMYC and HES1. [3, 4]. The
pathophysiologic effects of Notch activation include mainte-
nance of a pluripotent stem cell-like state [5] and the promotion
of angiogenesis [6, 7]. Inhibition of Notch signaling results in
decreased tumor growth in solid tumor xenograft models, in-
cluding pancreatic cancers [8].
Gamma secretase inhibition represents a novel approach to
Notch signaling disruption. RO4929097 is a potent inhibitor
of gamma secretase [9]. Intermittent and daily dosing in
xenograft models demonstrates antitumor activity [9].
Evaluation of RO4929097 in a phase I study demonstrated
good tolerability [10]. Common grade 1 to 2 toxicities were
fatigue, thrombocytopenia, fever, rash, chills, and anorexia.
Reported grade 3 toxicities were hypophosphatemia and grade
3 pruritus. Autoinduction, a phenomenon whereby prolonged
administration leads to decreased plasma exposures, has also
been observed [10, 11].
Our phase I study evaluates RO4929097 in combination
with gemcitabine in advanced solid tumors. Gemcitabine is
active as monotherapy in many malignancies including pan-
creatic cancer, non small-cell lung cancer, breast cancer, blad-
der cancer, ovarian cancer, cervical cancer, head and neck,
small cell lung cancer and mesothelioma [12]. A favourable
toxicity profile renders gemcitabine amenable to evaluation in
combination with targeted agents. Resistance to chemothera-
py may be possibly overcome by targeting key pathways to
inhibit stem cell propogation; hence the rationale for combin-
ing a gamma secretase inhibitor with chemotherapy.
Preclinical evidence suggests that gamma secretase inhibition
may specifically enhance the antitumor activity of
gemcitabine. Cook et al [13] recently evaluated xenograft
models treated with either gemcitabine, a gamma secretase
inhibitor, or gemcitabine combined with a gamma secretase
inhibitor. Although treatment with the gamma secretase inhib-
itor alone did not reduce tumor volume in this mouse model,
combination with gemcitabine prolonged animal survival
greater than either gamma secretase inhibition or gemcitabine
alone. The data also demonstrated the antivascular effects of
gamma secretase inhibition [14], one that was synergistic with
the co-administration with gemcitabine, leading to vascular
regression and intratumoral hypoxia. This further supports the
strategy of using a gamma secretase inhibitor in combination
with cytotoxic therapy as in the present phase I study.
We report the results of our phase I study evaluating the
oral gamma secretase inhibitor, RO4929097 in combination
with gemcitabine in advanced solid tumors. The primary
objective was to establish the maximum tolerated dose and
recommended phase II dose of RO4929097 in combination
with gemcitabine. The secondary objectives were to evaluate
safety, tolerability, pharmacokinetics, preliminary anti-tumor
activity of RO4929097 in combination with gemcitabine and




Key inclusion criteria were histologically or cytologically
proven advanced solid tumors with no further standard treat-
ment options available, age ≥18 years, life expectancy ≥
12 weeks, Eastern Cooperative Oncology Group performance
status ≤1, adequate organ and marrow function and the ability
to swallow medication. While no limitation on number of
prior lines of therapy was made, patients were required to be
≥4 weeks from systemic or radiotherapy and ≥6 weeks from
treatment with either nitrosourea or mitomycin C with the
exception of low dose, non-myelosuppressive radiotherapy.
Measurable disease was required.
Key exclusion criteria were prior treatment with a Notch
inhibitor, known brain metastases (due to poor prognosis and
the potential impact on evaluating neurologic adverse events),
history of allergic reactions to compounds similar to
RO4929097 or gemcitabine, patients taking medications with
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narrow therapeutic indices metabolized by cytochrome (CYP)
P450 or receiving strong CYP3A4 inducers and/or inhibitors
for which no medically appropriate alterative was available.
Patients with gastrointestinal syndromes, liver disease, known
HIV on antiretroviral therapy (due to the potential for phar-
macokinetic interactions with RO4929097), uncontrolled
electrolyte abnormality, uncontrolled grade ≥2 diarrhea, risk
of QT interval prolongation, or coexisting severe medical
conditions were excluded. Informed consent was required.
This study (PHL-078/CTEP 8575) is conducted by the
Princess Margaret Hospital Phase I Consortium with support
from the US National Cancer Institute U01 Cooperative
Agreement Award (U01-CA132123).
Dose escalation
A standard 3+3 dose escalation scheme was used. The
recommended phase II dose (RP2D) is the dose level at
which ≤1 of 6 patients experience a DLT. Intra-patient dose
escalation was not allowed. Patients received a fixed dose of
intravenous gemcitabine at 1,000 mg/m2 on days 1, 8 and 15
with daily oral dosing of RO4929097 on days 1–3, 8–10,
15–18 and 22–24 (3 on, 4 off continuous schedule) during a
28 day cycle. RO4929097 dosing occurred at approximately
the same time of the day, on an empty stomach either 1 h
before a meal or 2 h following a meal. Pre-planned
RO4929097 dose levels were 20 mg, 30 mg, 45 mg,
90 mg, 180 mg and 270 mg. The rationale for starting dose
and scheduling was based on the RP2D of the single agent
phase I trial [10]. Treatment continued until unacceptable
toxicity, study withdrawal, documented disease progression
or until study completion.
Definition of DLT
DLT was assessed during the first 28-day cycle. DLT was
defined as: grade 4 neutropenia lasting >7 days, febrile neu-
tropenia, grade 4 thrombocytopenia or thrombocytopenic
bleeding, grade ≥3 diarrhea despite management, grade ≥3
electrolyte abnormality unresolved within 72 h, any other
grade ≥3 non-hematologic toxicity judged to pose a safety
risk, failure to receive ≥75 % doses of RO4929097 or d8
gemcitabine in C1 due to treatment related toxicity or failure
to start C2 within ≤14 days due to treatment related toxicity.
Study assessments
Standard safety assessments were performed. Toxicity was
evaluated according to NCI Common Terminology Criteria
for Adverse Events (NCI CTCAE v.4). Radiographic assess-
ment of disease status was performed every 2 cycles and
antitumor effect was measured according to RECIST 1.1
criteria [15]. Prolonged stable disease was defined by stable
disease for 4 or more months. The data cutoff date for this
report was November 6, 2012.
Pharmacokinetic analysis of RO4929097 was performed
by collecting serial plasma during cycle 1 on day 1 and day 10.
RO4929097 is highly protein bound and therefore both total
and unbound RO4929097 were evaluated [11] Unbound
RO4929097 samples were obtained by filtering plasma sam-
ples using Amico Centrifree®Micropartition filtration devices
(Millipore Corp., Bedford, MA, USA) [16]. Total and un-
bound RO4929097 concentrations were determined using
validated HPLC-tandem mass spectrometry methods.
Pharmacokinetic parameters were calculated by non-
parametric methods using WinNonlin (Version 5.3,
Pharsight Corp., Sunnyvale, CA).
Plasma was collected on day 1 of cycles 1 and 2 for
circulating angiogenic factors IL-6, IL-8, VEGF-A, -C, -D,
bFGF and SDF-1 alpha. Quantitative analysis was performed
using Enzyme-Linked Immunosorbent Assays (ELISA)
(R&D Systems, Minneapolis, MN). The assays were
performed in duplicate according to the manufacturer’s in-
structions. Where duplicate values differed by more than
15 %, a triplicate was performed. If at least two results were
not within 15 % of each other, results were discarded. The
association between circulating angiogenic factor levels with
grade 3 or more adverse events was evaluated by theWilcoxon
test. The association between circulating angiogenic factor
levels with time to progression was evaluated by univariate
Cox proportional hazard analysis.
Notch pathway signaling was evaluated using three bio-
markers (Jagged1, Notch1- intracellular notch domain [ICD]
and Notch3) on archived paraffin-embedded specimens using
the Allred scoring system [17–19]. Correlation with outcome
was explored. The Wilcoxon rank test was used to compare
Notch pathway protein expression from patients with and with-
out either prolonged stable disease or response. Univariate Cox
proportional hazard analysis was used to correlate protein ex-
pression with time to progression.
Results
Study population
A total of 18 patients were enrolled at two participating in-
stitutions to determine the recommended phase II dose. Of
these, 3 patients received 20 mg RO4929097, 7 patients
received 30 mg RO4929097, 6 patients received 45 mg
RO4929097 and 2 patients received 90 mg RO4929097.
First patient, first visit was June 14, 2010. Mean age was
55 years. A median of 3 cycles (range 1–6) per patient was
delivered. Breast (5) and pancreatic (3) cancers were well
represented. Baseline characteristics for the study population
are summarized in Table 1.
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Dose escalation
Three patients were enrolled in dose level 1 (20 mg
RO4929097). No dose limiting toxicities were observed. Of
the three patients enrolled in the next dose level (30 mg), one
dose limiting toxicity of grade 3 transaminitis was observed.
The dose level was expanded to 6 patients at 30 mg with no
further dose limiting toxicities. One patient at the 30 mg dose
level discontinued study due to progressive disease causing
perforated viscous and death; this patient was non-evaluable
for toxicity and was replaced. The first 3 patients at dose level
3, (45 mg) had no dose limiting toxicities, thus the dose was
escalated to 90 mg where there were 2 dose limiting toxicities.
One patient experienced grade 3 transaminitis. The second
patient failed to receive 75 % of planned RO4929097 doses
secondary to prolonged neutropenia. Dosing was then de-
escalated to 45 mg RO4929097 and 3 additional patients were
treated. In this cohort, 2 dose limiting toxicities were ob-
served. One patient experienced a grade 3 transaminitis. The
second patient experienced a grade 3 maculopapular rash.
Observed dose limiting toxicities are summarized in Table 2.
The recommended phase II dose is 30 mg orally in a 3 day on,
4 day off, continuous schedule in combination with
intravenous gemcitabine dosed at 1,000 mg/m2 on days 1,
8 and 15 every 4 weeks.
Tolerability
Common toxicities at least possibly related to RO4929097
occurring in 10 % or more of patients included nausea, fatigue,
anorexia, vomiting, diarrhea, hypophosphatemia, hypomagne-
semia, rash and transaminitis. The frequency and grade
of common toxicities are summarized in Table 3.
Hypophosphatemia, transaminitis and rash were the most com-
mon (frequency 10 % or more) grade 3 adverse events. The
remaining toxicities were mild. All toxicities were reversible
with supportive measures, and interruption of study drug.
Pharmacokinetics
Pharmacokinetic analysis for total and free RO4929097 is
shown in Table 4. Pharmacokinetic analysis demonstrated that
repeated oral dosing of RO4929097 resulted in increased
exposures at increased doses. To evaluate the presence of
autoinduction, day 10:day 1 AUC 0-24 levels were compared
for both total and free RO4929097. In the absence of
autoinduction, day 10 levels are expected to equal or exceed
day 1 levels due to accumulation. Evaluation of Day 10: Day 1
total and free RO4929097 levels confirmed the presence of
autoinduction at dose levels 45 and 90 mg (Fig. 1a–b).
Circulating angiogenic factors
Quantitative ELISA analysis of circulating angiogenic fac-
tors IL-6, IL-8, VEGF-A, -C, -D, bFGF was performed on
serum samples collected on day 1 of cycles 1 and 2.
Circulating angiogenic factor levels were not associated
with the occurrence of grade 3 or higher adverse events or
time to progression (data not shown).
Table 1 Baseline characteristics of enrolled study patients
No. of patients
Total no. Patients enrolled 18
Male: Female 5:13
Mean age (Range) 55 (31–76)
ECOG performance status 0 4



















1 1 (20 mg) 3 0
2 2 (30 mg) 7 1 Transaminitis 3
3 3 (45 mg) 6 2 Transaminitis 3
Maculopapular rash 3
4 4 (90 mg) 2 2 Transaminitis 3
<75 % RO doses 3
Table 3 Common observed toxicities occurring in 10 % or more of
patients at least possibly related to RO4929097
Event Frequency (n) Frequency (n)
Any grade Grade ≥3
Nausea 61 % (11) 0
Fatigue 56 % (10) 0
Vomiting 39 % (7) 0
Hypophosphatemia 33 % (6) 6 % (1)
Anorexia 22 % (4) 0
Transaminitis 22 % (4) 6 % (1)
Maculopapular rash 17 % (3) 6 % (1)
Hypomagnesemia 11 % (2) 0
Acneiform rash 11 % (2) 0
Diarrhea 11 % (2) 0
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Notch signaling biomarkers
Jagged1, N1-ICD and Notch3, were evaluated by immunohis-
tochemistry in all available archival paraffin embedded patient
samples. Immunohistochemical staining scores for median
Notch3 scores were significantly higher in individuals who
received fewer than 4 cycles (score 7) compared to those
individuals who received 4 cycles of treatment of more (score
5) (p=0.029) (Fig. 2). For Jagged1 and N1-ICD, there were no
significant differences in staining scores identified when sam-
ples from patients receiving fewer than 4 cycles were compared
to those who received 4 or more cycles of treatment. Univariate
Cox proportional hazard ratios for time to progression and
Jagged1, N1-ICD and Notch3 were not statistically significant.
Table 4 Pharmacokinetic analysis of total and free RO4929097. Sample for 1 patient in DL 2 was not available for analysis. Cmax (ng/ml); AUC 0–24
(ng × hr/ml×104). Standard deviations in brackets
DL n Total D1 Total D10 Free D1 Free D10 Total D1 Total D10 Free D1 Free D10
Cmax Cmax Cmax Cmax AUC 0–24 AUC 0–24 AUC 0–24 AUC 0–24
1 3 552 (100) 615 (382) 46.7(7.6) 42.1(23.3) 6.8 (1.0) 9.9 (7.2) 540(60.0) 586(362)
2 6 833 (352) 1221(315) 54.7(20.3) 68.1(15.0) 12.6 (4.8) 19.2 (5.9) 644(295) 990(202)
3 6 986 (153) 1315(332) 71.6(30.6) 72.3(13.1) 12.8 (1.2) 16.5 (8.2) 924(369) 1687(157)
4 2 1635(742) 1205(290) 107.5(36.0) 80.7(28.7) 6.8 (1.0) 9.9 (7.2) 1697(875) 962(670)
20 mg 30 mg 45 mg 90 mg
20 mg 30 mg 45 mg 90 mg
a
b
Fig. 1 a day 10: day 1 area under the curve 0–24 for total
RO4929097. b day 10: day 1 area under the curve 0–24 for free
RO4929097
Fig. 2 Immunohistochemical staining for Notch Proteins a. Absence
of Notch 3 staining in oropharyngeal adenocarcinoma b. Weak diffuse
Notch 3 staining in squamous cell carcinoma c. Intermediate diffuse
staining for Notch 3 in metastatic breast ductal carcinoma d. Strong
diffuse staining for Notch 3 nasopharyngeal squamous cell carcinoma
e. Absence of staining for Notch 1- intracellular notch domain in
tracheal adenoid cystic carcinoma f. Weak staining for Jagged 1 in
low grade serous carcinoma of ovary
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Antitumor activity
Preliminary evidence of antitumor activity was observed
for RO4929097 in combination with gemcitabine. A
partial response was observed in one patient with naso-
pharyngeal carcinoma who was enrolled at the 45 mg
dose level. Prolonged stable disease was observed in
one patient with pancreatic cancer, one patient with
tracheal cancer and one patient with cervical cancer
(Fig. 3).
Discussion
We report the results of our phase I study of RO4929097, an
oral gamma secretase inhibitor, in combination with
gemcitabine in adult patients with advanced solid tumors.
The recommended phase II dose is 30 mg orally in a 3 day
on, 4 day off, continuous schedule in combination with
intravenous gemcitabine dosed at 1,000 mg/m2 on days 1,
8 and 15 every 4 weeks.
The combination of RO4929097 and gemcitabine was
tolerable, albeit with increasing toxicity at increasing dose
levels. Common observed toxicities included nausea, fa-
tigue, diarrhea, hypomagnesemia, hypophosphatemia and
transaminitis. No new toxicities were identified. These ef-
fects are similar to those identified with RO4929097 evalu-
ated as monotherapy in a phase I trial [10], in combination
with capecitabine [20], and are also similar to those ob-
served with other gamma secretase inhibitors [21]. The
intestinal goblet cell toxicity observed in preclinical models
has not proven to be a dose limiting toxicity in the clinical
evaluation of RO4929097. This may be due to the specific
RO4929097 scheduling using intermittent dosing on a 3 on,
4 off schedule or the lack of target engagement.
Efficacy results demonstrated response in one patient with
nasopharyngeal carcinoma and prolonged stable disease in 3
patients, one with each of pancreatic, tracheal and cervical
cancer. Patients with pancreatic cancer were specifically
recruited due to the evidence linking a strong role for Notch
signaling in pancreatic tumors [13]. The expected antitumour
activity due to Notch inhibition alone may be cytostatic. This is
supported by in vitro data demonstrating that RO4929097
treatment produced a more flattened phenotype, rather than
overt cell death, as well as by data showing that combination
treatment with RO4929097 and gemcitabine in a mouse xeno-
graft model of pancreatic cancer led to prolonged survival
despite the lack of decrease in tumor volume. In our study,
patients with prolonged stable disease may have experienced
some benefit fromRO4929097 therapy though confirmation of
this would require a randomized controlled study. Furthermore,
the additive impact of the investigational agent RO4929097,
with gemcitabine, a conventional cytotoxic chemotherapy with
efficacy in pancreatic and nasopharyngeal carcinomas, cannot
be delineated in this single arm phase I study.
While the exposures of RO4929097 achieved exceeded the
active levels identified in preclinical models, autoinduction
was observed starting at levels as low 45 mg. The intermittent
scheduling of 3 on, 4 off dosing was considered to minimize
the autoinduction observed in previous studies. However, in
our study, pharmacokinetic analysis of day 10: day 1 areas
under the curve for RO4929097 decreased below 1 with
increasing dose levels. These results are consistent with the
effect of autoinduction on RO4929097 metabolism with the
evaluated dose levels. As dose was increased over 45 mg,
autoinduction became more prominent. This pharmacokinetic
property of RO4929097 has been observed in another study,
with a minimum of 7 days of discontinuation required to
return to baseline kinetics [10]. Autoinduction presents a
challenge for both dose titration and the potential to combine
RO4929097 with agents metabolized by the liver.
We acknowledge some of the limitations of our pharmaco-
kinetic analysis; given that the half-life of RO4929097 is
approximately 20 h, we would require 4 to 5 half-lives of
pharmacokinetic sampling in order to accurately calculate
AUC 0-inf. We based our pharmacokinetic sampling schedule
on previous reports [9]; thus day 10:day1 ratios were used
with the assumption that day 10 exposures are expected to be
higher than day 1 exposures serves as a surrogate marker for
evaluating the presence of autoinduction. It is on the basis of
this definition that we identified the presence of autoinduction
at 45–90 mg of RO4929097 in this study.
Exploratory correlatives were analyzed to further evaluate
the pharmacodynamics of RO4929097. Correlative studies
demonstrated that higher levels of Notch3 protein expression
in archival tissue were associated with resistance to treatment
of RO4929097 in combination with gemcitabine in this study.
While this relationship is interesting and consistent with pre-
vious reports [22], it is an exploratory finding in this single
arm study designed primarily for dose finding. The
Fig. 3 Antitumor activity of RO4929097 in combination with
gemcitabine. Days on treatment are shown along the x axis
248 Invest New Drugs (2014) 32:243–249
significance of Notch amplification as a mechanism of resis-
tance may be further evaluated in a large randomized study.
The Notch axis is implicated in angiogenesis in conjunc-
tion with vascular endothelial growth factor signaling [14]. In
our study with a small number of responders, levels of circu-
lating angiogenic factors did not show correlation between
time to progression or statistically significant antiangiogenic
effects of RO4929097. This observation may be due to the
effect of autoinduction on decreasing steady state levels or
alternatively the absence of specific antiangiogenic drug ef-
fects. Treatment with RO4929097 has been shown to reduce
the expression of circulating angiogenesis factors in vitro
[9, 23]. Further studies are needed to further evaluate the
clinical antiangiogenic effects of Notch axis signaling.
In summary, the data from this phase I study demonstrates
that the oral gamma secretase inhibitor, RO4929097, can be
safely combined with gemcitabine in adult patients with ad-
vanced solid tumors. This is the first study to report the
combination of a notch inhibitor with intravenous chemother-
apy. The recommended phase II dose is 30 mg using a 3 day
on, 4 day off dosing schedule. While the exposures of
RO4929097 achieved exceeded the active levels identified
in preclinical models, autoinduction was observed starting at
levels as low 45 mg, limiting further titration. Antitumor
activity was seen in several tumor types including pancreas
and nasopharyngeal carcinoma, although activity due to
gemcitabine alone could not be excluded. Notch protein ex-
pression was lower in patients who achieved prolonged stable
disease or partial response, however evidence of target en-
gagement was not identified by analysis of circulating angio-
genic factor levels. Due to the discontinuation of RO4929097
drug development programs, a planned expansion at the
RPTD in a pancreatic cancer cohort did not proceed. Further
studies with other gamma secretase inhibitors in combination
with chemotherapy will be needed to expand the role of this
strategy in advanced solid tumours.
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